

## Immune Augmentation Therapy Table for Summary of Human Research

Return to [Summary of Research](#)

\*See legend below table for definitions of outcome codes

Ref. #	Sites	Patients	Stage	Patient Characteristics	Treatment	Outcome Assessed	Results
<b>Clinical Series</b>							
7	Various	79	Metastases.	IAT patients surveyed By phone		S*	50 (63%) alive with average 65 months survival after diagnosis. 50% improved performance status.
<b>Case Reports</b>							
6	Peritoneal Mesothelioma	11	Not known	Histologic confirmation	IAT by injection	S	Mean survival of 30 months, range seven - 80 months. Compared to survival range of one – 60 months in literature.

\*Legend

CODE	RESPONSE OR OUTCOME
CR	Complete Response
PR	Partial Response
SD	Stable Disease
DP	Disease Progression
OS	Objective Stabilization
OR	Objective Response
MR	Mixed Response
POS R	Positive Response
DT	Discontinued Treatment
U	Unknown
EXP	Expired
DR	Disease Response
S	Survival

[Back to the Top](#)